
Novo Nordisk Reports Positive Trial Results for Childhood Obesity Drug
Novo Nordisk announced positive Phase 3 trial data showing that semaglutide significantly reduced obesity rates among young children. Approximately 40 percent of participants achieved a healthy BMI range when combining the treatment with lifestyle modifications.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (54/100)Sources
Novo Nordisk says semaglutide cut obesity rates in young children in trial - reuters.com
Novo Nordisk says semaglutide cut obesity rates in young children in trial reuters.com
Read full article →Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial - WSJ
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial WSJ
Read full article →Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial - morningstar.com
Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial morningstar.com
Read full article →Novo Nordisk says semaglutide cut obesity rates in young children in trial
By Reuters
Read full article →Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification - taiwannews.com.tw
Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification taiwannews.com.tw
Read full article →Coverage Timeline
Related Stories

Volkswagen Considers Selling Ducati in Strategic Portfolio Review
15m ago

Novartis Reports Late-Stage Trial Failure for Neuromuscular Drug Candidate
28m ago

Canada imposes retaliatory tariffs on US goods; Trump threatens Bombardier
47m ago

Flight Recorders Recovered from Amazon Cargo Plane Crash in Miami
1h ago